TheraRadar
Data updated: Mar 29, 2026

AK-FLUOR 10%

FLUORESCEIN SODIUM
Approved 2008-08-08

INDICATIONS For testing tear film stability by determining the fluorescein break-up time (FBUT)....

Source: FDA Label • LONG GROVE PHARMS
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
17
Years on Market

Details

Status
Prescription
First Approved
2008-08-08
Routes
INTRAVENOUS
Dosage Forms
INJECTABLE

Companies

LONG GROVE PHARMS
Active Ingredient: FLUORESCEIN SODIUM

AK-FLUOR 10% Approval History

Loading approval history...

What AK-FLUOR 10% Treats

1 FDA approvals

Originally approved for its first indication in 2008 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AK-FLUOR 10% FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

INDICATIONS For testing tear film stability by determining the fluorescein break-up time (FBUT).

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA022186 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.